C85.90 — Lymphoma
Approved61M · medication — R-CHOP chemotherapy
Insurer Rationale
The requested first-line immunochemotherapy is approved following biopsy confirmation and specialist haematology review.
Reasoning Chain
This approval is clinically aligned. Tissue diagnosis is complete, staging is documented, and the treatment request follows the standard first-line haematology pathway rather than jumping ahead of diagnostic certainty.
Reasoning Chain
Findings
Biopsy-confirmed lymphoma, B symptoms, Widespread nodal disease, Performance status adequate
Diagnosis
Lymphoma (histologically confirmed)
Assessment
Staging and treatment readiness review — First-line systemic therapy is appropriate because diagnosis and staging are complete.
Guideline action
Proceed with specialist-led first-line immunochemotherapy
Verdict
Approval is clinically correct because the request follows definitive diagnosis and accepted first-line lymphoma management.
Clinical Evidence
ESMO Clinical Practice Guideline — Diffuse Large B-cell Lymphoma (2023)
First-line systemic therapy
Standard immunochemotherapy is appropriate once histology and staging support treatment.
NCCN Guideline — B-Cell Lymphomas (2025)
Initial therapy
Biopsy-confirmed advanced-stage lymphoma should proceed to first-line regimen selection without unnecessary delay.